Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 2/26/24 → 2/26/27 |
Funding
- Boehringer-Ingelheim: $113,816.00
23-MULTI-62-BI-PMC (1438-0005): An Open-label, Multi-center Phase II Dose Selection Trial of Intravenous BI 764532, a DLL3-targeting T Cell Engager, in Patients With Relapsed/Refractory Extensive-stage Small Cell Lung Cancer and in Patients With Other Rel
- Anthony, Lowell (PI)